71/100
✓ Peer-reviewed
alzhub usefulness score 71 out of 100.
·
JAMA neurology
·
2021-05-01
Intensive treatment was associated with a small but statistically significant greater decrease in hippocampal volume compared with standard treatment, consistent with the observation that intensive treatment is associated with greater decreases in total brain volume. 5 key findings →
Design: meta-analysis
Participants: 1,267
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
71/100
✓ Peer-reviewed
alzhub usefulness score 71 out of 100.
·
JAMA
·
2001-11-01
Progressive dementia was detected by PET with a sensitivity of 93% (191/206) and a specificity of 76% (59/78). 4 key findings →
Design: longitudinal study
Participants: 146
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Full text may need a subscription
71/100
✓ Peer-reviewed
alzhub usefulness score 71 out of 100.
·
JAMA
·
2018-09-01
In secondary analyses, the area under the curve (AUC) of [18F]flortaucipir SUVR was compared with 3 established magnetic resonance imaging measures (hippocampal volumes and AD signature and whole-brain cortical thickness), and sensitivity and specificity of [18F]flortaucipir in MCI due to AD vs non-AD neurodegenerative disorders were determined. 3 key findings →
Design: cross-sectional
Participants: 719
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
(18)F-Flutemetamol performs similarly to the (11)C-PIB parent molecule within the same subjects and provides high test-retest replicability and potentially much wider accessibility for clinical and research use. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies →
Original source
Full text may need a subscription
71/100
✓ Peer-reviewed
alzhub usefulness score 71 out of 100.
·
JAMA
·
2003-03-01
Compared with abstention, consumption of 1 to 6 drinks weekly is associated with a lower risk of incident dementia among older adults. 5 key findings →
Design: cohort study
Participants: 5,888
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Full text may need a subscription
The literature has several methodological limitations including lack of sufficient algorithm development descriptions and standard definitions. 1 key finding →
Participants: 255
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
In clinical samples, people with amnestic MCI are at high risk of developing Alzheimer's disease dementia, with annual rates of progression from MCI to Alzheimer's disease estimated at approximately 10% to 15% compared with the base incidence rates of Alzheimer's disease dementia of 1% to 2% per year. 5 key findings →
Design: cohort study
Participants: 33
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
71/100
✓ Peer-reviewed
alzhub usefulness score 71 out of 100.
·
Stroke
·
2020-06-10
Periventricular white matter hyperintensities (WMH; PVWMH) and deep WMH (DWMH) are regional classifications of WMH and reflect proposed differences in cause. 4 key findings →
Design: meta-analysis
Participants: 26,654
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
It is currently unclear whether plasma biomarkers can be used as independent prognostic tools to predict changes associated with early Alzheimer's disease. 4 key findings →
Design: longitudinal study
Participants: 123
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
71/100
✓ Peer-reviewed
alzhub usefulness score 71 out of 100.
·
Neurology
·
2022-06-03
In the precuneus, we observed an inverted U-shaped pattern of novelty-related activity across groups, with higher activity in SCD and MCI compared with HC, but not in patients with AD who showed relatively lower activity than MCI. 3 key findings →
Design: longitudinal study
Participants: 499
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
We demonstrated that higher amyloid burden as measured by both CSF amyloid beta 42/40 ratio and non-displaceable binding potential in the posterior cingulate cortex was associated with lower functional connectivity in the default mode network. 3 key findings →
Design: longitudinal study
Participants: 173
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
71/100
✓ Peer-reviewed
alzhub usefulness score 71 out of 100.
·
Nature medicine
·
2021-04-29
Alzheimer's disease (AD) is characterized by the spread of tau pathology throughout the cerebral cortex. 2 key findings →
Design: longitudinal study
Participants: 1,612
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Addition of CAT to the PACC provides unique information about early cognitive decline not currently captured by the episodic memory, executive function, and global cognition components and may therefore improve detection of early Aβ-related cognitive decline. 1 key finding →
Design: longitudinal study
Participants: 70
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Plasma p-tau217 showed the strongest individual association with Aβ PET status (area under the curve [AUC], 0.85). 5 key findings →
Design: cohort study
Participants: 1,407
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
The best-performing MRI-free approaches had high continuous and dichotomous agreement with MRI-dependent SUVRs for Aβ PET and temporal flortaucipir (R2 ≥0.95; ± agreement ≥92%) and for Alzheimer's disease-related effect sizes; agreement was slightly lower for entorhinal flortaucipir and longitudinal slopes. 2 key findings →
Design: longitudinal study
Participants: 1,290
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
There were 571 participants in the normal cognition group, 625 participants in the subjective cognitive decline group, 155 participants in the objectively defined subtle cognitive decline group, 501 participants in the mild cognitive impairment group, 471 participants in Alzheimer's disease group, and 128 participants with cognitive impairment from other known causes. 5 key findings →
Design: longitudinal study
Participants: 4,386
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Alzheimer's disease is a common brain disorder affecting many people worldwide. 1 key finding →
Design: systematic review
Evidence: high
Full summary, score breakdown and related studies →
Original source
Ten studies assessing retinal properties in dementia were included. 5 key findings →
Design: systematic review
Evidence: high
Full summary, score breakdown and related studies →
Original source
The cognitive reserve (CR) hypothesis posits that individuals can differ in how their brain function is disrupted by pathology associated with aging and neurodegeneration. 3 key findings →
Design: longitudinal study
Participants: 490
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
The A+P+T- group showed a slower rate of increase in tau-PET compared to the A+P+T+ group, primarily in neocortical regions. 4 key findings →
Design: longitudinal study
Participants: 231
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Our findings suggest that plasma, CSF, and neuroimaging biomarkers differ considerably within the ATN framework; the most accurate target biomarkers for diagnosing AD were the CSF-A, neuroimaging-T, and neuroimaging-N within each ATN modality. 4 key findings →
Design: longitudinal study
Participants: 2,340
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
These findings indicate that plasma pTau181, plasma pTau217 and amyloid-β PET convey overlapping information and therefore predict the dynamic phase of asymptomatic amyloid-β accumulation with comparable performances. 1 key finding →
Design: cohort study
Participants: 75
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
71/100
✓ Peer-reviewed
alzhub usefulness score 71 out of 100.
·
JAMA neurology
·
2021-02-01
Substantial flortaucipir accumulation in temporal regions is greatest in persons aged 65 to 85 years who were CU and had high initial Aβ PET levels, compared with those with lower Aβ levels. 4 key findings →
Design: cohort study
Participants: 167
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
The apolipoprotein E gene ( APOE ) is the most important genetic risk factor for sporadic Alzheimer disease, with the ε4 allele being associated with increased cerebral amyloid-β and tau pathologies. 5 key findings →
Design: cohort study
Participants: 277
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Neuropathology and neuroimaging studies have identified several subtypes of Alzheimer's disease (AD): hippocampal sparing AD, typical AD, and limbic predominant AD. 2 key findings →
Design: systematic review
Evidence: high
Full summary, score breakdown and related studies →
Original source
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor,
and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a
scientist can tell a landmark trial from a conference abstract without having to already know the
difference. Every point comes from one of 20 components, all of them printed on the study itself,
so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we
could not verify current impact factors from a source we control, and an invented one would be
worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science,
Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed
journal. A separate part scores how much the journal's own papers are cited, which tells the
tier-3 journals apart.
Two rules we don't bend. First, we never fill in a
missing value: if a record does not state a sample size or a design, that component scores
zero, and if we simply have no data for a part, such as a citation count, that part is left out and
the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed
article is capped at 16/100 and carries a warning chip — so a conference abstract or
a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not
work — above an early positive finding. Someone deciding whether to buy a supplement is served by
that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is
reproducible: the same file always yields the same numbers.
See the whole rubric drawn out →
— four charts covering all 30,580 studies: how the scores are spread and where the cap
bites, which of the 20 components the library is strong and weak on, which subjects rest on
stronger evidence, and what kinds of study each subject is actually built from.